Volume 5 Supplement 1

2nd International Conference of cGMP Generators, Effectors and Therapeutic Implications

Open Access

Enhanced vascular cGMP/cGK I signaling and hypotonia in cysteine-rich-protein 2-deficient mice

  • Matthias Sausbier1Email author,
  • Hong Zhao1,
  • Rudolf Schubert2,
  • Ulrike Sausbier1,
  • U Abdullah1,
  • Andrea Huber4,
  • Susi Feil3,
  • Robert Feil3,
  • Franz Hofmann3,
  • Winfried Neuhuber4,
  • Hans-Dieter Allescher and
  • Peter Ruth1
BMC Pharmacology20055(Suppl 1):P48

https://doi.org/10.1186/1471-2210-5-S1-P48

Published: 16 June 2005

The NO/cGMP signaling pathway plays an important role in vasorelaxation and blood pressure regulation. The predominant effector of cGMP in vascular smooth muscle is cGMP kinase I (cGK I). Established substrates of cGK I in vascular smooth muscle are the large-conductance voltage- and Ca2+-activated (BK) potassium channel, the IP3-receptor-associated cGMP kinase substrate (IRAG) and the myosin phophatase 1 M. Previously, we identified the cysteine-rich protein 2 (CRP2) in blood vessels as a new substrate of cGK I which is specifically phosphorylated by cGK I in vivo. However, the physiological role of CRP2 and its involvement in regulation of vascular tone as an effector of cGMP/cGK I signaling was not known. To elucidate the functional role of CRP2 in vascular smooth muscle, we generated CRP2-deficient (CRP2-/-) mice. The myogenic tone of CRP2-/- tibial small arteries towards stepwise pressure changes revealed no differences when compared to wild type (wt). Unexpectedly, cGMP-mediated relaxation was enhanced in CRP2-/- tibial small arteries and A. saphena. In contrast to cGMP, the cAMP-mediated relaxation was not affected in these vessels. Long-term radiotelemetric recordings revealed a significantly decreased mean arterial pressure (MAP) and an enhanced NO/cGMP signaling in CRP2-/- mice compared to wt. In-depth analysis revealed increased protein levels of cGK I, whereas the expression of cGK I targets such as BK channel and IRAG was not altered in CRP2-/- vessels compared to wt. Interactor screens with CRP2 as a bait revealed a specific interaction with a translation initiation factor. These findings suggest that CRP2 is a specific effector of the vascular NO/cGMP/cGK I signaling in vivo. CRP2 seems to be involved in the regulation of the NO/cGMP/cGK I signaling pathway by modulating cGK I expression. In addition, the CRP2-/- mouse line may serve as an animal model for hypotonia.

Authors’ Affiliations

(1)
Pharmakologie und Toxikologie, Pharmazeutisches Institut der Universität Tübingen
(2)
Institut für Physiologie, Universität Rostock
(3)
Institut für Pharmakologie und Toxikologie, TU München
(4)
Institut für Anatomie, Universität Erlangen

Copyright

© BioMed Central Ltd 2005

Advertisement